Department of Endocrinology. Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
Department of Neurosurgery. Hospital Ramón y Cajal, Madrid, Spain.
Endocrine. 2018 Sep;61(3):407-421. doi: 10.1007/s12020-018-1645-x. Epub 2018 Jun 16.
Giant pituitary adenomas comprise about 6-10% of all pituitary tumors. They are mostly clinically non-functioning adenomas and occur predominantly in males. The presenting symptoms are usually secondary to compression of neighboring structures, but also due to partial or total hypopituitarism. Functioning adenomas give rise to specific symptoms of hormonal hypersecretion. The use of dopamine agonists is considered a first-line treatment in patients with giant macroprolactinomas. Somatostatin analogs can also be used as primary treatment in cases of growth hormone and thyrotropin producing giant adenomas, although remission of the disease is not achieved in the vast majority of these patients. Neurosurgical treatment, either through transsphenoidal or transcranial surgery, continues to be the treatment of choice in the majority of patients with giant pituitary adenomas. The intrinsic complexity of these tumors requires the use of different therapies in a combined or sequential way. A multimodal approach and a therapeutic strategy involving a multidisciplinary team of expert professionals form the basis of the therapeutic success in these patients.
巨大垂体腺瘤占所有垂体肿瘤的 6-10%。它们主要是无功能性腺瘤,主要发生在男性中。主要表现为邻近结构受压的症状,但也可因部分或全部垂体功能减退引起。功能性腺瘤会引起激素分泌过多的特定症状。多巴胺激动剂的使用被认为是巨大泌乳素瘤患者的一线治疗方法。生长抑素类似物也可作为生长激素和促甲状腺素产生的巨大腺瘤的主要治疗方法,尽管绝大多数此类患者的疾病无法缓解。神经外科治疗,无论是通过经蝶窦还是经颅手术,仍然是大多数巨大垂体腺瘤患者的首选治疗方法。这些肿瘤的内在复杂性要求以联合或序贯的方式使用不同的治疗方法。多模式方法和涉及多学科专家团队的治疗策略是这些患者治疗成功的基础。